Journal Guide

Current Psychopharmacology publishes peer-reviewed expert full-length/mini reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology.

Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.

Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal aims to publish the highest quality review articles, drug clinical trial studies and guest edited thematic issues in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.

Current Therapeutic Research serves an international audience of scientists and clinicians in a variety of research, academic and clinical practice settings by quickly disseminating research findings. The journal provides a home for the rapid publication ofOriginal reports of recent development in drug therapy, including papers presenting unexpected, controversial, provocative and/or negative resultsResearch letters, presenting research that may stimulate further investigation or alert readers to clinically relevant but preliminary findingsIn-depth review articles on specific drug therapies or disease statesApplied health economics papers, aimed at a clinical audienceTrials From Resource-Limited Settings intended to highlight original medical and pharmaceutical reports from resource-limited settings.CTR is a peer-reviewed, author pays, online journal and the final published article will be universally accessible on all of Elsevier's platforms. In addition, the articles are indexed by all major biomedical abstracting databases.Published articles range from studies exploring new drugs and new indications for existing drugs to large, multicenter Phase III and IV trials. The journal also encourages submission of brief reports and commentaries on topics that are timely or provocative. For further information click on the links belowOriginal ResearchReview Articles and Meta-analysesCommentariesBrief ReportsResearch LettersLetters to the Editor

Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.Coverage includes:• Novel therapeutic strategies• High-throughput screening• Therapeutic targets• Combinatorial chemistry, parallel synthesis and library design• Drug delivery• ADME/Tox• Advances in key compound classes and therapeutic areas• Genomics and proteomics• Automation and technology• Virtual chemistry• Informatics• Business strategy• Clinical trialsand other aspects of drug discovery.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterestSubmission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at:http://www.drugdiscoverytoday.com/submit-a-paper/

An important reference for all pharmacology and toxicology departments, DMD is also a valuable resource for medicinal chemists involved in drug design and biochemists with an interest in drug metabolism, expression of drug metabolizing enzymes, and regulation of drug metabolizing enzyme gene expression. Articles provide experimental results from in vitro and in vivo systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals.

Thank you for your cooperation. (The degraded operation period has changed.

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

• Overviews of contentious or emerging issues. 
• Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
• In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
• Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
• Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
• Editorials and commentaries on topical issues.

Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.The rationale for this extensive coverage is the conviction that drug, alcohol and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a single journal in a format that is understandable and which has received rigorous editorial review. The hope of its editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices.The accepted abbreviation for Drug and Alcohol Dependence for bibliographic citation is Drug Alcohol Depend.Drug and Alcohol Dependence is currently being distributed to all the members of the College on Problems of Drug Dependence (CPDD), the oldest scientific organization in the United States concerned with research on problems of drug dependence. Members of the CPDD are provided with both the print version as well as access to the full text of the current issue and back issues dating back to Vol. 46, Issue no. 1 of the online version as a benefit of membership.

Drug and Chemical Toxicology publishes full-length research papers, review articles and short communications that encompass a broad spectrum of toxicological data surrounding risk assessment and harmful exposure. Manuscripts are considered according to their relevance to the journal.

For nearly 50 years, DTB has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB was started in 1962. From the outset, it has provided healthcare professionals with independent, clear, reliable information and advice to help ensure patients get the best care. DTB conclusions represent a synthesis of the best available medical evidence with opinions from a wide range of commentators. Published monthly by BMJ, DTB is wholly independent of industry, Government and regulatory authorities and does not carry any display advertising or accept any form of commercial sponsorship.DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice.Surveys of our readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments. These are just a few of the examples of why DTB is regarded as an indispensable part of evidence-based clinical practice and has been described as both essential reading for practising doctors and as a key information source by the House of Commons Health Select Committee in the UK.

Drugs in R&D is an international, peer reviewed, open access, online only journal, which provides timely information on emerging drug classes and new treatments for specific disorders in an ‘open access’ format for all to review. Original research and reviews from all phases of clinical development are included, with a strong link to clinical practice. Healthcare decision makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.Journal issues comprise:·        Original research on new drugs, including clinical trials:·        New research on established drugs.·        R&D Insight reports:Short communications and letters to the editor are welcomed and will be considered for publication. Reviews may also be considered. All manuscripts are subject to peer review by international experts.

The journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.